Sector: MedicalVical Incorporated (NASDAQ: VICL)
Headlines
- Vical Completes Final Patient Follow-Up in TransVax(TM) CMV Vaccine Phase 2 Trial
Nov 23, 2009 06:31 AM | VICL
- AeroVironment shares rise on upgrade
Nov 17, 2009 01:31 PM | AVAV, CIEN, VICL
- Vical Added to NASDAQ Biotechnology Index
Nov 16, 2009 06:32 AM | VICL
- Semi-Annual Changes to the NASDAQ Biotechnology Index
Nov 13, 2009 08:02 PM | CSKI, HITK, NDAQ, PARD, SIGA, SPPI
- Vical's DNA Vaccine Technology Addresses Challenges of Emerging Diseases
Nov 10, 2009 06:31 AM | VICL
- Vical Reports Third Quarter 2009 Financial Results and Progress in Key Development Programs
Nov 04, 2009 06:31 AM | VICL
- Vical Announces News Release and Conference Call Schedule for Third Quarter 2009 Financial Results
Oct 28, 2009 06:31 AM | VICL
- Vical to Present at BIOCOM Investor Conference
Oct 27, 2009 06:31 AM | VICL
- Vical's Vaxfectin(R) Adjuvant Drives 200-Fold Increase in Antibody Responses With Sanofi-Pasteur Fluzone(R) Seasonal Influenza Vaccine
Oct 26, 2009 06:32 AM | VICL
- VICL, DNDN, BKD, RINO, ASPM, IFLO, HITK, AFFX: Seven Bullish Healthcare Stocks
Oct 12, 2009 11:40 AM | AFFX, ASPM, BKD, DNDN, HITK, IFLO
- RidgewaterEquity.Com Free Fundamental Sector &Amp; Market Research on GSI, UFS, WHR, ZQK, SONC and VICL
Oct 09, 2009 08:14 AM | GSI, SONC, UFS, VICL, WHR, ZQK
- Vical Reports Second Quarter 2009 Financial Results and Updates Progress in Key Programs
Aug 06, 2009 06:30 AM | VICL
- StockPreacher.com Issues Trading Outlook for Novavax Inc.
Aug 03, 2009 06:51 AM | CRXL, MRK, NVAX, QDEL, VICL
- Vical and Teva Establish Sales and Marketing Agreement for Allovectin-7(r) in Israel
Aug 03, 2009 06:30 AM | VICL
- Vical Announces News Release and Conference Call Schedule For Second Quarter 2009 Financial Results
Jul 30, 2009 06:30 AM | VICL
- Federated Kaufmann Funds to Invest $10 Million in Vical
Jul 28, 2009 06:31 AM | VICL
- Vical TransVax(tm) CMV Vaccine Achieves Promising Interim Clinical Results in Phase 2 Trial
Jul 08, 2009 06:30 AM | VICL
- Vical Announces News Release and Conference Call/Webcast Schedule to Present TransVax(tm) CMV Vaccine Phase 2 Interim Efficacy Results
Jul 07, 2009 06:30 AM | VICL
- Vical H1 Influenza Vaccine Delivers Robust Preclinical Results With 100% Response
Jun 30, 2009 06:31 AM | VICL
- Vical Receives Milestone Payment From Merck & Co., Inc.
Jun 22, 2009 06:30 AM | VICL
- Form 4 ROLLAND ALAIN P PHD For: Oct 04 (10K)
Oct 06, 2009 07:31 PM
- Form 4 SAMANT VIJAY B For: Oct 05 (10K)
Oct 06, 2009 07:31 PM
- Form 4 VICAL INC For: Jul 24 Filed by: MARXE AUSTIN W & GREENHOUSE DAVID M (10K)
Jul 28, 2009 05:41 PM
- Form 4 VICAL INC For: Jun 12 Filed by: MARXE AUSTIN W & GREENHOUSE DAVID M (10K)
Jun 16, 2009 05:38 PM
- Form 4 VICAL INC For: May 21 Filed by: LYONS GARY A (10K)
May 28, 2009 06:32 PM
- Form 4 VICAL INC For: May 21 Filed by: CAMPBELL ROBERT H (10K)
May 28, 2009 06:20 PM
- Form 4 DOUGLAS R GORDON For: May 21 (10K)
May 28, 2009 06:05 PM
- Form 4 MERTON ROBERT C For: May 21 (10K)
May 28, 2009 06:03 PM
- Form 4 VICAL INC For: May 20 Filed by: TEMASEK HOLDINGS (PRIVATE) LTD (10K)
May 22, 2009 05:44 PM
- Form 4 VICAL INC For: May 18 Filed by: TEMASEK HOLDINGS (PRIVATE) LTD (10K)
May 20, 2009 05:43 PM
Analyst Ratings
Sentiment Survey
|
|
|
|
|
|
|
|
|
|
|
Share Performance
|
Period
|
VICL
|
Compare to S&P
|
| YTD |
117.73 %
|
80.20 %
|
| 4 Weeks |
-5.25 %
|
-6.27 %
|
| 12 Weeks |
-31.01 %
|
-34.96 %
|
|
Financial Ratios
Earnings Performance
|
EPS Growth in Last Quarter: 0.00 %
|
|
EPS Growth in Last Year: 41.67 %
|
|
Sales Growth in Last Quarter: -1.89 %
|
|
Sales Growth in Last Quarter: 448.95 %
|
|
